VERAXA Biotech AG (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has announced new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates (ADCs) in cancer treatment. The announcement comes as the company prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026 in San Diego (https://nnw.fm/APy2D).
The newly released data showed that VERAXA’s BiTAC-ADC technology was able to distinguish between breast cancer cells and healthy cells in laboratory studies and demonstrated dose-dependent destruction of three-dimensional tumor cell spheroids. While the platform remains in early development, the results underscore the potential of VERAXA’s proprietary BiTAC approach, which is designed to improve the precision of antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells.
VERAXA maintains a diversified oncology pipeline of antibody-based formats including ADCs, T-cell engagers (TCEs), and other antibody-based formats. The company recently began trading on the NASDAQ Capital Market under the ticker symbol VRXA following the completion of its business combination with Voyager Acquisition Corp.
The BiTAC-ADC platform represents a significant advancement in the field of antibody-drug conjugates, which have shown promise in cancer treatment but often suffer from off-target toxicities. By improving selectivity, VERAXA aims to enhance the therapeutic index of ADCs, potentially leading to more effective and safer treatments for patients. The ability to spare healthy cells while destroying cancer cells in three-dimensional spheroid models is a critical step toward demonstrating the platform’s clinical potential.
VERAXA is also presenting its BiTAC-TCE platform at the BIO International Convention, highlighting its broader pipeline of next-generation cancer therapies. The company is actively seeking strategic collaborations to further develop its technologies and bring them to market. As VERAXA continues to advance its pipeline, the new data provide a foundation for discussions with potential partners who are interested in precision oncology.
For investors and industry observers, the progress of VERAXA’s BiTAC platforms signals a potential shift toward more targeted cancer therapies that could reduce side effects and improve patient outcomes. The company’s recent listing on NASDAQ provides it with access to capital markets to support ongoing research and development. More information about VERAXA and its pipeline is available in the company’s newsroom at https://nnw.fm/VRXA.
